Regencell Corp (RGC): Price-to-Revenue Ratio
Competing with the behemoths of classical neurology creates extreme survival risks for Regencell Bioscience (RGC). This historical P/S chart illustrates the dynamics of market expectations, where the level reflects the current multiple. The asset relies on a narrow niche of treating autism through Chinese medicine methods, which triggers skepticism among Western investors and establishes its reputation as a highly speculative instrument.
Metric breakdowns and analytics for Regencell (RGC)
- current price and projected stock value:
- stock exchange capitalization data:
- issuer book value statistics:
- business debt structure and liquidity details:
Total Debt to Capital Coefficient Regencell Bioscience|RGC - Long-Term Debt to Equity|Current Liabilities to Capital Regencell Corp|RGC - Company Debts|Debts to Net Assets Regencell|RGC - Company Long-Term Debts|Company Current Liabilities Regencell Bioscience|Interim Coverage Ratio regencellbioscience.com
- earnings and valuation multiples information:
RGC - Net Profit|Expected Net Profit Regencell Bioscience|RGC - Price to Earnings Ratio|Price to Future Earnings Ratio Regencell Bioscience Ltd|RGC - PEG Multiple|Enterprise Value to EBITDA Ratio Regencell|RGC - Operating profit EBITDA|Net earnings per one share for the last twelve months Regencell Bioscience|RGC - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months regencellbioscience.com|RGC - Earnings growth in current year|Net earnings per one share growth forecast for next year Regencell Bioscience
- issuer revenue and sales details:
Fundamental company analysis:RGC, regencellbioscience.com
For Regencell Bioscience (RGC), whose revenues depend on innovative medical cycles rather than the broader economy, revenue serves as the primary valuation basis. The ratio of market capitalization to sales volume, illustrated through the company's rolling P/S, allows investors to filter out price noise and determine the fair value of the business relative to its operational scale, where low values signal potential for a price recovery.
Competing companies
Price-to-Revenue Ratio BIIB (biogen.com)|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|Axsome - Price-to-Revenue Ratio|ACAD: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio XENE (Xenon Corp)|VKTX: P/S Multiple|SUPN (supernus.com) - Price-to-Revenue Ratio|CPRX (Catalyst Pharmaceuticals, Inc.) - P/S Multiple|Denali (DNLI) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Harmony Pharma (HRMY)|BHVN - Price to Sales|Price-to-Revenue Ratio Amylyx Pharmaceuticals AMLX|Price-to-Revenue Coefficient trevitherapeutics.com (TRVI)|Praxis Precision Medicines, Inc. - P/S Multiple|Anavex (AVXL) - Market Cap to Revenue|CBLL: P/S Multiple|PRTA - Price-to-Revenue Coefficient|ALEC (Alector Inc.) - P/S Multiple|Price to Sales annexonbio.com ANNX|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Inc - Market Cap to Revenue Ratio|P/S Multiple ACIU (AC Immune Corp)|VYGR - Market Cap to Revenue|Neumora Therapeutics - P/S Multiple|Price to Sales scilexholding.com|Tevogen Bio (TVGN) - Price-to-Revenue Ratio|Alpha Cognition Inc. - Market Capitalization-to-Revenue Ratio|CGTX (Cognition Therapeutics, Inc.) - P/S Multiple|IKT - Price-to-Revenue Multiple|P/S Multiple SAVA|Market Cap to Revenue assertiotx.com ASRT|Price-to-Revenue Ratio Coya Therapeutics COYA|VTGN: Market Cap to Revenue Ratio|Ovid Rx - P/S Multiple|Price to Sales Acumen Pharmaceuticals, Inc|CRVO (CervoMed Inc.) - Market Cap to Revenue|Alterity Therapeutics Limited (ATHE) - P/S Multiple|Price-to-Revenue Ratio Clene Inc|PEPG: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|RLMD - Price to Sales|Price-to-Revenue Ratio Annovis Bio, Inc. ANVS|Market Capitalization-to-Revenue Ratio GRCE|Firefly Neuroscience - P/S Multiple|Price to Sales Klotho Neurosciences Inc|NRSN: P/S Multiple|Price-to-Revenue Multiple Reviva Pharmaceuticals, Inc. RVPH|MTVA (MetaVia Inc.) - P/S Multiple|Price to Sales neuraxis.com NRXS|Price-to-Revenue Ratio Helius Medical (HSDT)|passagebio.com - Market Cap to Revenue Ratio|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV - Market Cap to Revenue|Athira Pharma, Inc. - P/S Multiple|Price to Sales addextherapeutics.com|alzamend.com (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Price-to-Revenue Ratio KTTA|Market Cap to Revenue CRGT (Cortigent, Inc.)|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|Cara Therapeutics Inc. - Price-to-Revenue Ratio|Chromocell Therapeutics Corporation - P/S Multiple|Price-to-Revenue Coefficient Eliem Therapeutics ELYM|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Price to Sales longboardpharma.com (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc (NKGN) - Price-to-Revenue Coefficient|P/S Multiple NRBO|Market Cap to Revenue Sage Therapeutics Inc SAGE|P/S Multiple SNPX (Synaptogenix, Inc.)|Price-to-Revenue Coefficient trevena.com (TRVN)|Vigil Neuro - P/S Multiple|Price to Sales anewmeds.com|Cerevel (CERE) - Price-to-Revenue Ratio
